SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Enterprise value to EBITDA ratio
Percentile
P33
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | -1.48 | -38.5% |
| 2024 | -1.06 | -420.4% |
| 2023 | 0.33 | +130.4% |
| 2022 | -1.09 | +94.7% |
| 2021 | -20.72 | -200.3% |
| 2020 | 20.66 | +138.5% |
| 2019 | -53.74 | - |